scholarly journals Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients

2017 ◽  
Vol 27 (4) ◽  
Author(s):  
Hosein Shabaninejad ◽  
Asra Asgharzadeh ◽  
Nima Rezaei ◽  
Aziz Rezapour
Keyword(s):  
Replacement Therapy ◽  
Primary Immunodeficiency ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement ◽  
The Cost

Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment

2021 ◽  
Vol 42 (6) ◽  
pp. 489-494 ◽  
Author(s):  
Richard L. Wasserman
Keyword(s):  
Replacement Therapy ◽  
Primary Immunodeficiency ◽  
New Products ◽  
Relevant Literature ◽  
Clinical History ◽  
Laboratory Evaluation ◽  
Burden Of Care ◽  
Continue Treatment ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement

Background: Immunoglobulin replacement therapy (IGRT) is the foundation of treatment for the majority of patients with primary immunodeficiency. Clinical history and laboratory evaluation define the patients for whom IGRT is necessary and appropriate. During the 70 years since the first patient was treated, new products have led to the development of several modes of administration that facilitate the individualization of treatment that enables the optimization of care. Objective: The objective was to explain the assessment of candidates for IGRT and approaches to reevaluating recipients of IGRT to decide on the need to continue treatment and to review the approaches to optimize IGRT. Methods: The relevant literature was reviewed in the context of the author's experience supervising > 20,000 IGRT treatments over a 40-year period. Results: Providing the most appropriate form of IGRT for individual patients ameliorates disease and lessens the burden of care for patients with primary immunodeficiency. Conclusion: IGRT is safe and effective when used to treat patients with primary immunodeficiency who meet established and appropriate clinical and laboratory criteria.

scholarly journals Intravenous Immunoglobulin Replacement Therapy in Children with Primary Immunodeficiency Diseases: A Nurse's Guide

2018 ◽  
Vol 2 (2) ◽  
pp. 149-156
Author(s):  
Ana Marija Hošnjak ◽  
Snježana Čukljek ◽  
Sanja Ledinski Fičko ◽  
Martina Smrekar ◽  
Nikolina Veriga ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Intravenous Immunoglobulin ◽  
Primary Immunodeficiency ◽  
Primary Immunodeficiency Diseases ◽  
Immunodeficiency Diseases ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement

Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases

2007 ◽  
Vol 27 (5) ◽  
pp. 503-509 ◽  
Author(s):  
Melvin Berger ◽  
Charlotte Cunningham-Rundles ◽  
Francisco A Bonilla ◽  
Isaac Melamed ◽  
Johann Bichler ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Primary Immunodeficiency ◽  
Primary Immunodeficiency Diseases ◽  
Immunodeficiency Diseases ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement

scholarly journals Infections in Secondary Immunodeficiency Patients Treated with IgPro10: A Real-Word Analysis of Patients, Including Those with Hematological Malignancies

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4071-4071
Author(s):  
Betsy Lahue ◽  
Rajiv Mallick ◽  
Xiang Zhang ◽  
Andrew S. Koenig ◽  
Gabriela Espinoza
Keyword(s):  
Replacement Therapy ◽  
Infection Rate ◽  
Primary Immunodeficiency ◽  
Index Date ◽  
Secondary Immunodeficiency ◽  
Underlying Condition ◽  
Immunoglobulin Replacement Therapy ◽  
Severe Infections ◽  
Immunoglobulin Replacement ◽  
Privately Held

Abstract Secondary immunodeficiency (SID) is an acquired condition caused by several factors including, but not limited to, B-cell malignancies, and may result in frequent, burdensome, and possibly life-threatening infections. Treatment guidelines recommend immunoglobulin replacement therapy (IgRT) in certain settings to prevent recurrent, persistent, or major (severe) infections. This retrospective analysis of a US healthcare database characterized patients (pts) with suspected SID, who experienced infections, and were or were not treated with IgRT (IgPro10 [Privigen ®]). Data were collected from 26 US healthcare organizations from TriNetX DataWorks™ Network between 1/1/09 - 1/31/20. Pts were required to have the following: suspected SID (defined as ≥1 underlying conditions related to SID such as: solid organ transplant [SOT], non-Hodgkin lymphoma [NHL], multiple myeloma [MM], and chronic lymphocytic leukemia [CLL]), ≥1 severe infection (defined as requiring hospitalization and/or treatment with intravenous antibiotics or anti-viral medication) or ≥2 non-severe infections between underlying condition diagnosis date and the index date, the absence of diagnosed primary immunodeficiency, and an available medical history of ≥12 months pre-index and ≥3 months post-index. The index date refers to first IgPro10 use or the corresponding date for pts not receiving IgPro10 (unexposed cohort). In the IgPro10 cohort, pts were required to have had ≥2 consecutive IgPro10 administrations within 90 days. Between the pre- and post-index periods, the following variables were compared for both cohorts: pts' treatment, underlying conditions, baseline characteristics, and change in annualized infection rate (for infections of any severity and severe infections). Pre-index immunoglobulin G (IgG) (or calculated globulin [CG]) levels were recorded as: hypogammaglobulinemia (HGG) (IgG <6 g/L or CG <18 g/L), normal (IgG ≥6 g/L or CG ≥18 g/L), or missing. A generalized estimation equation (GEE) model with logit link was used to compare the change in the proportion of pts with an annualized infection rate of zero from the pre- to the post-index period across both cohorts. The final sample comprised 222 IgPro10 pts and 11,226 unexposed pts. In the IgPro10 cohort, 143 pts were on IgPro10 for <6 months, 41 pts for 6-12 months, and 38 pts for >12 months. In both the IgPro10 and the unexposed cohorts, SOT was the most frequent underlying condition (45.5% and 44.6%, respectively), followed by NHL (21.6% and 28.2%, respectively), MM (14.4% and 10.1%, respectively), and CLL (11.3% and 7.6%, respectively). Age (mean [SD], 57.2 [13.9] vs 57.9 [17.0] years old, respectively) and sex distribution (male:female, 56.3%:43.7% vs 51%:48.8%, respectively) were similar in the IgPro10 and unexposed cohort. During the pre-index period, the IgPro10 cohort, compared with the unexposed cohort, received a greater number of antibiotic courses (median [interquartile range], 7 [20] vs 1 [5], respectively), had a substantially higher proportion of pts with HGG (HGG: 34.7% vs 3.0%; normal IgG: 43.7% vs 57.8%; missing: 21.6% vs 39.2%, respectively), and a lower proportion of pts with an annualized infection rate of zero (for infections of any severity and severe infections) (Figure 1). There was an approximate four-fold increase in the proportion of pts with no infections of any severity following IgPro10 administration; this increase was significantly larger than in the unexposed cohort (p<0.0001) (Figure 1). Additionally, there was an increase in the proportion of pts with no severe infections following IgPro10 administration. Again, this increase was significantly larger than in the unexposed cohort (p<0.0001) (Figure 1). This real-world study found that compared with pts not receiving IgRT, pts who subsequently went on to receive IgPro10 experienced more infections pre-treatment. Following IgPro10 administration, more pts had an annualized infection rate of zero (for infections of any severity or severe infections) compared with the pre-index period. Moreover, the increase in the proportion of pts with no infections was greater in the IgPro10 cohort than in the unexposed cohort, for both infections of any severity and severe infections. Taken together, these findings suggest effectiveness of IgPro10 in pts with SID, but further study, such as a prospective randomized controlled trial, is needed to confirm these initial findings. Figure 1 Figure 1. Disclosures Lahue: CSL Behring: Consultancy; Alkemi Health: Current Employment, Current holder of stock options in a privately-held company. Mallick: CSL Behring: Current Employment, Current holder of individual stocks in a privately-held company. Zhang: CSL Behring: Current Employment, Current holder of individual stocks in a privately-held company. Koenig: CSL Behring: Current Employment, Current holder of individual stocks in a privately-held company. Espinoza: CSL Behring: Current Employment, Current holder of individual stocks in a privately-held company. OffLabel Disclosure: IgPro10 (Privigen®, CSL Behring, King of Prussia, PA, U.S.), a type of immunoglobulin replacement therapy, is currently approved in the U.S. to treat patients with primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and chronic immune thrombocytopenic purpura (ITP).

Sign in / Sign up

Export Citation Format

Share Document